AMD

Key opinion leaders discuss factors to consider when selecting treatments in wet AMD including insurance considerations and degree of clinical response.

Panelists consider the theoretical systemic safety of anti-VEGF agents in wet AMD and discuss their role in the management of patients with risk factors.

Experts compare the safety and efficacy of agents currently available for wet AMD treatment and emphasize the importance of post-marketing surveillance.

Panelists give insight into the role of anti-VEGF therapy for wet AMD treatment and share personal experiences counseling patients on the goals of therapy.

Experts share best practices for managing the treatment burden of wet AMD including treat-and-extend, loading doses, monitoring, and hybrid telemedicine.

A panel of experts considers the impact of COVID-19 on wet AMD management and discusses the potential for telemedicine and home monitoring devices.

Key opinion leaders in ophthalmology provide an overview of age-related macular degeneration and comment on clinical recommendations for assessing symptoms.

LumiThera has announced positive interim data in visual and ERG clinical outcomes in the ELECTROLIGHT pilot study in dry AMD patients.

Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.